PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models

Abstract Background The MET receptor tyrosine kinase represents a promising target in cancer. PIK3CA activating mutations are common in several tumor types and can potentially confer resistance to anti-receptor tyrosine kinase therapy. Methods MET and/or PI3K pathway inhibition was assessed in NIH3T...

Full description

Bibliographic Details
Main Authors: Lluís Nisa, Pascal Häfliger, Michaela Poliaková, Roland Giger, Paola Francica, Daniel Matthias Aebersold, Roch-Philippe Charles, Yitzhak Zimmer, Michaela Medová
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Molecular Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12943-017-0660-5